183 results about "Prolonged-release tablet" patented technology

The invention relates to a sustained-release tablet capable of avoiding sudden release of a medicine after being taken together with an alcoholic beverage, the sustained-release tablet comprises a sustained-release tablet core and an anti-sudden-release material coating layer wrapping the sustained-release tablet core, and the anti-sudden-release material is composed of a polysaccharide substance and a cellulose derivative, the polysaccharide substance is selected from one or more of guar gum, xanthan gum and Arabic gum, the cellulose derivative is selected from one or more of hydroxypropyl methylcellulose, ethyl cellulose and hydroxyethyl cellulose, and the weight ratio of the polysaccharide substance to the cellulose derivative is 1: 1-10: 1. The sustained-release tablet disclosed by the invention has an excellent burst release resisting effect when being taken together with an alcoholic beverage, and the clinical medication safety and effectiveness of a preparation are improved.

The invention relates to the field of pharmaceutical preparations, in particular to a diclofenac sodium sustained release tablet and a preparation method thereof. The diclofenac sodium sustained release tablet is prepared from the following components: diclofenac sodium, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, mannitol, organic acid salt, a flow aid and a lubricant. The diclofenac sodium sustained-release tablet provided by the invention can be stably released, has an excellent sustained-release effect, and is simple in preparation process, low in cost and suitable for industrial mass production.

The invention relates to the field of pharmacy, and discloses a felodipine sustained release tablet and a preparation method thereof.The felodipine sustained release tablet comprises a tablet core and a film coating layer wrapped outside the tablet core, and the tablet core comprises the following components in parts by mass: 3.5-5.0 parts of felodipine nanocrystals; 50 to 65 parts of modified hydroxypropyl methylcellulose; the preparation method comprises the following steps: S1, preparing felodipine nanocrystals: dissolving felodipine in an organic solvent, and carrying out anti-solvent precipitation and high-pressure homogenization treatment, so as to obtain a nanocrystal suspension; drug nanocrystals are embedded between silicate layers through an ultrasonic embedding technology, and burst release is inhibited by combining physical confinement and electrostatic adsorption; the gradient pore skeleton constructs a pore layer-by-layer decreasing structure through fluidized bed multi-temperature zone deposition, the release rate is accurately regulated and controlled, and collapse is avoided; the ionic liquid stabilizer is introduced, and the problems of nanocrystal aggregation and degradation are synchronously solved through hydrogen bond anchoring and an antioxidant function.

The present invention discloses a tofacitinib citrate sustained-release tablet preparation and a preparation method thereof, which belongs to the technical field of pharmaceutical preparations. The sustained-release tablet comprises a double-layer core and a coating layer; the double-layer core comprises a drug-containing layer and a push layer; wherein the drug-containing layer comprises: tofacitinib citrate, an adhesive, polyethylene oxide, a glidant and a lubricant; the push layer comprises: mannitol, an adhesive, red iron oxide, polyethylene oxide, a glidant and a lubricant; the coating layer comprises: cellulose acetate, a pore-forming agent, a plasticizer, water and acetone. The sustained-release tablet preparation of the present invention solves the technical problems existing in the prior art by adopting a double-layer osmotic pump prescription design, adopting non-hygroscopic materials such as mannitol, adopting a standard round tablet design, preparing a sustained-release coating layer without using methanol, and adopting a coating machine for coating and curing.

The invention relates to the technical field of pharmacy, and discloses a carbidopa-levodopa sustained release tablet and a preparation method thereof.The carbidopa-levodopa sustained release tablet is prepared from, by mass, 65.4%-68.0% of levodopa, 17.0%-18.5% of carbidopa, 0.1%-0.5% of an adhesive, 0.1%-0.5% of a lubricant and 0.1%-0.5% of a coloring agent. And the mass percentage of the sustained-release material is 8.0%-9.0%. According to the carbidopa-levodopa sustained-release tablet and the preparation method thereof, polyvinyl acetate-crotonic acid copolymer is selected as a sustained-release material, hydroxypropyl cellulose is selected as an adhesive, the defects existing in the prior art are overcome, the carbidopa-levodopa sustained-release tablet can well control slow release of carbidopa and levodopa, and the sustained-release effect is good. According to the present invention, the release curve is highly consistent with the release curve of the original development agent, such that the safety and the effectiveness of the medication can be significantly improved, the wet granulation process is adopted, the addition mode of the adhesive is adjusted, the granulation process problem that the granulation is not easily performed when the active component content is large is solved, the preparation process is simple, and the industrial production is easy.

The invention relates to the technical field of press machines, and discloses a tablet processing device for producing compound patch colon sustained-release tablets, which comprises an operation table, an extrusion mechanism, a forming mechanism and a feeding mechanism, and the forming mechanism comprises a forming mold, an ejection assembly, a supporting assembly and an overturning driving assembly, the forming mold is rotationally installed on the operation table, a plurality of rows of forming hole sets are formed in the top face of the forming mold, and each forming hole set comprises a plurality of forming holes distributed at equal intervals. In the forming mechanism, upward movement and resetting of the extrusion mechanism serve as a power source, the forming mold is firstly driven to turn to a discharging posture, then the ejection assembly is driven to actively generate downward thrust on tablets in all the forming holes at the same time, so that the function that the tablets are rapidly and automatically separated from the forming holes is achieved, tablet forming is not affected, and the forming efficiency is improved. And the pressure-resistant and pressure-resistant sealing device can be used for a long time, does not need to be replaced frequently, and is lower in use cost.

The gastric retention type sustained-release tablet comprises a blank retention layer and a drug-loaded sustained-release layer which are arranged on the surface layer of a plain tablet of the gastric retention type sustained-release tablet, the blank retention layer is prepared from the following raw materials: a skeleton type slow-release material, a floating aid and an expanding agent; the medicine-carrying sustained-release layer is prepared from the following raw materials: a skeleton type sustained-release material, a floating aid and an active medicine component. According to the invention, calcium silicate with low bulk density and super absorbent resin are respectively used as a floating aid and an expanding agent, so that the gastric retention type sustained-release tablet has similar gastric retention capability with a common single-layer tablet, and has a very good sustained-release effect at the same time; through the arrangement of the blank retention layer and the drug-loaded sustained-release layer, the sustained release of drugs with low solubility in acid can also be realized in the form of gastric retention type sustained-release tablets.

The invention discloses a gastric retention double-layer sustained-release tablet and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations, the active ingredient of the gastric retention double-layer sustained-release tablet is 3-[4-[4-(lH-benzotriazole-1-yl) butyl] piperazine-1-yl] benzisothiazole hydrochloride, and the gastric retention double-layer sustained-release tablet is composed of a quick-release drug release layer and a sustained-release drug release layer, the quick release layer contains an active component, a filler I and a disintegrating agent; and the sustained-release layer contains an active component, a filler II, an expansion material, a release retardant, an expansion accelerator and a stabilizer. According to the gastro-retention double-layer sustained-release tablet, the quick-release layer can quickly release the medicine to reach the effective blood concentration, and the retention time of the tablet in the stomach is prolonged after the sustained-release layer expands, so that the in-vivo absorption window of the medicine is prolonged, the maintenance of the blood concentration is realized, the in-vivo half-life period of active ingredients is remarkably prolonged, the administration frequency can be reduced, and the compliance of a patient is improved. The product is simple in preparation process, suitable for industrial production and wide in development prospect.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a carbidopa-levodopa pharmaceutical composition and a preparation method thereof.The carbidopa-levodopa pharmaceutical composition is composed of carbidopa, levodopa, a sustained-release material, an adhesive, a coloring agent and magnesium stearate, the sustained-release material is selected from one or a combination of two of hydroxypropyl cellulose MF and hydroxypropyl cellulose LF, and the adhesive is cellulose; in percentage by weight, the dosage of the slow-release material hydroxypropyl cellulose MF is 0.1-20.0%; and in percentage by weight, the dosage of the slow-release material hydroxypropyl cellulose LF is 0.1-20.0%. According to the carbidopa-levodopa sustained-release tablet disclosed by the invention, original and auxiliary bags in the prescription are accessible, the cost is low, the preparation process is simple and controllable, commercialized mass production can be realized, and the quality of the prepared product is consistent with that of the Ninning.

The present invention relates to the technical field of pharmaceutic preparations, and provides a pregabalin pharmaceutical composition and a preparation method therefor. According to the present invention, by compounding sustained-release polymer materials having different viscosity grades for use, stable release performance can be obtained, slow release within 24 hours is realized, the requirement of once daily administration is satisfied, the release of the compound is smoother than that of LYRICA CR tablets, and the dissolution rate in 24 hours is also superior to that of the LYRICA CR tablets. The dissolution curves F2 of pregabalin sustained-release tablets of different sizes, which are prepared according to the present invention, in different media (0.06 M HCl, pH 4.5, pH 6.8) are all greater than 50, so that the requirements for waiving BE studies for different sizes are met.

The invention relates to the technical field of oral non-biological medicine preparations, in particular to an upatinib sustained release tablet and a preparation method thereof. The invention discloses a preparation method of an upatinib sustained-release tablet, and aims to solve the problem that the dissolution rate of the upatinib sustained-release tablet is unstable, namely, the upatinib sustained-release tablet can stably control the release of upatinib in different gastrointestinal tract environments through the synergistic cooperation of all the components of the upatinib sustained-release tablet, and the preparation method of the upatinib sustained-release tablet is relatively low in cost and easy to operate. The large-scale production is facilitated; the upatinib sustained release tablet comprises the following components in percentage by weight: 3.0%-3.5% of upatinib, 18%-19.50% of a pH regulator, 50%-55% of a filler, 17%-22% of an adhesive, 0.1%-1% of a flow aid, 1%-2% of a lubricant and 0.01%-10.9% of a coating material.

The invention relates to the technical field of mannitol preparation, and particularly discloses a preparation method of medicine auxiliary modified mannitol, the mannitol comprises the following components in parts by mass: 100-120 parts of mannitol, 5-10 parts of polyethylene glycol PEG, 2-5 parts of sodium carboxymethyl cellulose CMC-Na, 3-7 parts of cyclodextrin, 1-3 parts of nano silicon dioxide, 10-20 parts of plant source microcrystalline cellulose, and 1-5 parts of chitosan; through compound modification, the hardness and compressive strength of mannitol in the tablet are remarkably improved, the fragmentation phenomenon in transportation and storage is reduced, the integrity of the tablet is ensured, the powder fluidity is improved by adding nano silicon dioxide, and the plasticity of the preparation in industrial production is better; under the synergistic effect of cyclodextrin and chitosan, the dissolving property of mannitol is improved, so that the medicine disintegration is more uniform, and the preparation method is suitable for different dosage forms such as oral instant tablets and enteric sustained-release tablets; and the adjustability of the disintegration time after modification meets the diversified requirements from quick release to slow release.

The application discloses a salbutamol sulfate sustained-release tablet and a preparation process thereof. The preparation process comprises the following steps: drug micronization treatment, drug and ion exchange resin compounding, granulation with hydrophilic gel matrix material, gradient temperature control drying, total mixing after whole granulation, tabletting, double controlled-release coating, ladder solidification treatment and screening and packaging. Through the synergistic sustained-release effect of the ion exchange resin and the hydrophilic gel matrix material, the double controlled-release coating and the ladder solidification process, the application effectively inhibits drug burst release, realizes smooth and long-lasting release, reduces impurity content, and improves product stability and batch reproducibility. The obtained sustained-release tablet releases 20%-40% in 2 hours and 80% or more in 8 hours in a pH 6.8 phosphate buffer, and the quality is controllable, so the sustained-release tablet is suitable for industrial production.

The utility model discloses a tablet press feed hopper for sustained release tablet production, which relates to the technical field of sustained release tablet production and comprises a feed hopper, a mounting seat is arranged at the bottom of the feed hopper, a connecting top cover is arranged at the top of the feed hopper, a connecting sleeve is arranged at the bottom of the connecting top cover, and a positioning bolt is arranged outside the connecting sleeve. An anti-blocking assembly is arranged on the top of the connecting top cover, a pulling handle is installed on one side of the top of the connecting top cover, and the pulling handle and the anti-blocking assembly are arranged adjacently. Raw materials accumulated in the feeding hopper are conveyed through the arranged anti-blocking assembly, the rotating rod and the spiral conveying paddle are driven by the arranged driving motor to rotate, so that the raw materials are conveyed, and meanwhile the raw materials are prevented from being accumulated in the feeding hopper, blocking is caused, and the discharging efficiency is affected; the spiral conveying paddle is used in cooperation with the cleaning scraping plate, and the raw material station is prevented from adhering to the inner wall of the feeding hopper.

This application relates to the field of pharmaceutical equipment technology, and discloses an apparatus and method for granulating sustained-release drugs, to solve the problem of rapid drug release from sustained-release tablets due to short compression time and lack of compaction. A granulation structure is fixedly installed inside a housing. The granulation structure includes a fixed plate, a support shaft, a rotating gear, and a granulation belt. The granulation belt has a granulation groove, and two granulation belts are installed in a V-shape. Powdered sustained-release drug is discharged into the granulation groove. A power motor drives the support shaft, rotating gear, and granulation belt to rotate in opposite directions, causing the granulation groove to compress the powdered sustained-release drug in the granulation groove. As the granulation groove moves from the top to the bottom of the granulation belt, the compressive force on the powdered sustained-release drug increases, and the compression time of the powdered sustained-release drug in the granulation groove is extended, so that the powdered sustained-release drug is compacted, preventing breakage of the compressed sustained-release tablets.

The invention discloses an eplerenone and dapagliflozin compound sustained-release tablet and a preparation method thereof. The eplerenone and dapagliflozin compound sustained-release tablet sequentially comprises a drug-containing pill core, a sustained-release coating layer, a tabletting auxiliary material layer and a coating layer from inside to outside, the drug-containing pellet core is prepared from a first filling agent, dapagliflozin propylene glycol monohydrate, eplerenone and an adhesive; the adhesive is formed by combining hydroxypropyl methylcellulose E3 or hydroxypropyl methylcellulose E5 with hydroxypropyl methylcellulose K4M; the sustained-release coating layer comprises a sustained-release coating material, a pore-foaming agent and a solubilizer; the tabletting auxiliary material layer comprises a second filling agent, a flow aid, a disintegrating agent and a lubricating agent; the disintegrating agent is prepared from low-substituted hydroxy propyl cellulose and cross-linked sodium carboxymethyl cellulose. According to the eplerenone and dapagliflozin compound sustained release tablet prepared by the invention, the content of dapagliflozin is uniform, the dissolution curve of eplerenone and dapagliflozin is completely released within 24 hours, meanwhile, the problems of layering and cracking of tablets during tabletting are solved, and the product stability is improved.

The invention discloses a norfloxacin preparation as well as a preparation method and application thereof, and belongs to the technical field of medicines. The norfloxacin preparation comprises a skeleton sustained-release tablet and a regulation and control layer wrapping the surface of the skeleton sustained-release tablet, the main drug of the matrix sustained release tablet is crystal form X norfloxacin. According to the norfloxacin preparation, through a mode of combining a skeleton and membrane control, the aim of slowly releasing the drug by combining the skeleton and the membrane control is fulfilled while the drug is enhanced to cope with the influence of environmental water, heat and oxygen, and the dissolution behavior similar to that of an existing reference preparation can be achieved.

The invention provides a pharmaceutical composition for treating Parkinson's disease and a preparation method of the pharmaceutical composition. Carbidopa-levodopa sustained-release tablets prepared from the pharmaceutical composition have an in-vitro drug release curve similar to that of a reference preparation 'Ninine', bioequivalence and better stability. In the preparation process, each batch has better content uniformity; raw materials and auxiliary materials are easy to obtain, the production process is simple, and commercialized production is facilitated.

The invention discloses a centrifugal granulation process for producing slow-release indapamide, which comprises the following steps: S1, stirring and mixing indapamide, a slow-release framework material, a lubricant and a filler; s2, putting the mixed powder into a disc of a granulation device, and performing low-speed centrifugal granulation in a vacuum state to form a mother nucleus; s3, transferring the mother nucleus to a high-pressure state for centrifugal granulation; s4, performing low-temperature drying on the granules; and S5, after drying, tabletting by using a tablet press, and finally coating and packaging by using double aluminum to obtain the indapamide sustained-release tablet. According to the invention, high and low pressure conversion is carried out in the centrifugal granulation process, so that gas in the sustained-release tablet is reduced, the density is increased synchronously, and the sustained-release capability and the efficacy durability of the tablet are improved.

The invention provides a cefditoren pivoxil sustained-release tablet which comprises cefditoren pivoxil, a crystal transformation inhibiting material, a framework material, a pore-foaming agent, an adhesive, an antioxidant and a lubricant, the crystal transformation inhibiting material, the framework material and the adhesive are all polyoxyethylene, the pore-foaming agent is polyethylene glycol 8000, the antioxidant is polyethylene glycol 8000, and the lubricant is polyethylene glycol 8000. The cefditoren pivoxil crystal form can effectively overcome the defect that an existing cefditoren pivoxil preparation is taken many times, can ensure the stability of the cefditoren pivoxil crystal form, can reduce the variety of auxiliary materials in the preparation, and is suitable for commercial production.

A modified-release tablet dosage form containing tolcapone is disclosed. The tablet dosage form provides a pulsatile, pH-dependent release profile of tolcapone to both the gastric cavity and the small intestine. Methods for treating or preventing a disease selected from transthyretin amyloidosis (ATTR), Parkinson's disease, and obsessive-compulsive disorder using the dosage form are provided.

The invention discloses an ingredient mixing device and method for sodium valproate sustained release tablet production, and relates to the field of pharmaceutical equipment.The ingredient mixing device comprises a mixing main body, the top of the mixing main body is connected with a top cover through a plurality of bolts, the bottom of the top cover penetrates through the bottom and is fixedly connected with a feeding cylinder, and a main shaft is arranged in the center of the interior of the mixing main body; four outer plates are fixedly connected to the outer surface of the main shaft at equal intervals, and a mixed discharging switching structure is arranged in the mixing main body. By arranging the mixing and discharging switching structure, rapid switching between a mixing mode and a discharging mode is achieved, and the structure allows a channel to be opened in the mixing stage so that materials can be subjected to sufficient convection, and allows the channel to be closed in the discharging stage so that the materials can be guided to an outlet; due to the integrated design, the tedious step that materials need to be transferred to another device for discharging after mixing in a traditional technology is avoided, the risks of procedure interruption, material loss and cross contamination are remarkably reduced, and the continuity and the overall efficiency of the production process are greatly improved.

The utility model discloses a kind of layered compression devices of multilayer sustained-release tablet, belong to pharmaceutical equipment technical field.This kind of layered compression device of multilayer sustained-release tablet, including processing table, the bottom end of processing table is equipped with support frame, the top end middle part of processing table is rotatably connected with pivot, the top end of pivot is equipped with carousel, the top end outside of carousel is equipped with several compression grooves, the inside bottom end of compression groove is equipped with ejection plate, the bottom end of pivot is through the bottom end of processing table, the bottom end of processing table is equipped with adjusting mechanism for rotating pivot, the top end of carousel is equipped with pusher mechanism, the bottom end side of processing table is equipped with first electric telescopic rod, the top end of processing table is through the output of first electric telescopic rod, the output of first electric telescopic rod and the bottom end of ejection plate are contacted, the side of processing table is equipped with stand, the side top end of stand is equipped with horizontal plate, the utility model can effectively realize automatic discharge function, improve discharging efficiency, with higher practical value.

The present invention relates to the technical field of preparation of antihypertensive sustained-release drugs, and in particular to a kind of indapamide sustained-release tablet production equipment, including a tablet pressing device used in a production step, the tablet pressing device includes a top plate fixedly connected to the top of a support, a vibration motor fixedly connected to the top of the top plate, the top plate and a hopper fixedly connected, two groups of clamps fixedly connected to one side of the support, a quantitative disk rotatably connected between the two groups of clamps, the top of the clamp and the bottom of the hopper are fitted, and a mold barrel is provided below the bottom opening of the clamp. The present invention conveys raw material powder through the cooperation of the quantitative disk and the two groups of clamps, after starting the vibration motor, during the rotation of the quantitative disk, the holes inside the quantitative disk can be filled with raw material powder, and then the powder is fully sent to the inside of the mold barrel, effectively preventing the adhesion of the powder on the surface of the conveying device, avoiding the situation of insufficient addition of raw materials, and reducing the possibility of quality problems of finished tablets.

The invention discloses a doxazosin mesylate sustained-release tablet and a preparation process thereof, and relates to the technical field of doxazosin mesylate sustained-release tablets.The sustained-release tablet comprises a double-layer tablet core composed of a first sustained-release layer and a second sustained-release layer; the double-layer tablet core is prepared from the following components in parts by mass: a first slow-release layer and a second slow-release layer; the first slow-release layer is prepared from the following components in parts by mass: 2.4 parts of chitosan-TPP modified doxazosin mesylate, 10 to 12.5 parts of citric acid-cassava starch, 12.5 to 15 parts of magnesium aluminum silicate-cassava starch, 40 to 60 parts of microcrystalline cellulose and 3 to 4 parts of magnesium stearate; the second slow-release layer is prepared from the following components in parts by weight: 2.4 parts of chitosan-TPP modified doxazosin mesylate, 1.44 to 3.36 parts of carrageenan, 130 to 140 parts of polyethylene oxide, 30 to 40 parts of sodium alginate, 55 to 65 parts of citric acid, 67 to 77 parts of microcrystalline cellulose and 3 to 4 parts of magnesium stearate.

The invention relates to an epalrestat sustained release tablet and a preparation method thereof. The epalrestat sustained-release tablet is composed of 20-30 parts by weight of epalrestat, 10-50 parts by weight of a sustained-release framework material, 30-60 parts by weight of a filler, 3 parts by weight of an adhesive and 1-5 parts by weight of a lubricant. The preparation method comprises the following steps: uniformly mixing the epalrestat, the sustained-release framework material and the filler according to the prescription dosage, adding the adhesive to prepare a soft material, granulating, drying, adding the lubricant, uniformly mixing, and tabletting to obtain the epalrestat sustained-release tablet. The epalrestat sustained-release tablet is simple in prescription, only contains epalrestat, the sustained-release framework material, the filler, the adhesive and the lubricant, and is low in auxiliary material cost; the adopted preparation process is simple, low in technical difficulty, low in production cost and suitable for industrial production. Compared with an epalrestat quick-release preparation, the epalrestat sustained-release tablet prepared by the invention has the characteristics of stable in-vivo and in-vitro drug release, high bioavailability, reduced medication frequency and improved medication compliance of patients.

The fragrance filter element comprises a filter element body and fragrance materials filled in the filter element body, the filter element body comprises a fragrance bottle, a filter element ring and a fairing, the filter element ring is arranged between the fragrance bottle and the fairing in a sleeved mode, the fairing is arranged on the upper portion of the fragrance bottle, and a rectification mixing cavity is formed between the inner wall of the fairing and the outer wall of the fragrance bottle. A slow release hole is formed in the top end of the fragrance bottle to communicate the rectification mixing cavity with a fragrance bottle cavity in the rectification mixing cavity, a fragrance material is placed in the fragrance bottle, and a rectification water outlet hole is formed in the rectification cover; an upper sustained-release tablet is arranged in the fragrance bottle, and an anti-overflow cavity is formed between the upper sustained-release tablet and the sustained-release hole; water enters the rectification mixing cavity from the filter element ring, the fragrance material in the fragrance bottle cavity is gradually dissolved through the slow release holes, and then the fragrance material is mixed into water and flows out through the rectification water outlet hole. The fragrance filter element is installed in the shower head in a replaceable mode, water in the shower head cannot directly enter the interior of the fragrance filter element from the bottom of the fragrance filter element to impact and dissolve the fragrance material, the fragrance material can be dissolved in the water permanently and stably, and a user can use the fragrance filter element conveniently.

The present invention relates to the field of pharmaceutical technology, and discloses fluvastatin sodium sustained-release tablets and a preparation method. The weight ratio of the raw materials of the sustained-release tablets is as follows: 25-29 parts of cellulose derivatives; 5-9 parts of polyethylene substances; 20-24 parts of fluvastatin sodium; 20-25 parts of fillers; 1-3 parts of binders; 1-1.2 parts of disintegrants; 2-3 parts of lubricants. Weigh all the raw material components according to the raw material ratio, and mix the above components evenly in sequence. Granulate the powder mixed in the previous step by dry granulation to form uniform granules. Use a fluidized bed coating device to evenly coat the coating material on the surface of the granules to form a moisture-proof and sustained-release functional coating layer. Put the coated granules into a tablet press and press them into the shape and thickness of the tablets preset by the manufacturer, and control the pressure and temperature at the same time to prepare the sustained-release tablets. Conduct quality inspection on the prepared fluvastatin sodium sustained-release tablets. Finally, perform aluminum-plastic packaging on the qualified sustained-release tablets after quality inspection and store them in a cool and dry place.

This invention relates to an utpatinib sustained-release tablet and its preparation method, belonging to the field of pharmaceutical formulation technology. The sustained-release tablet comprises a core and a coating layer. The core is formed by mixing and pressing drug-containing sustained-release particles with excipients. The drug-containing sustained-release particles are prepared by wet granulation and drying of utpatinib hemihydrate, hydroxypropyl methylcellulose, and small-particle-size microcrystalline cellulose, with the residual moisture content of the particles controlled at 1.0%–3.0% (w / w). The excipients include anhydrous citric acid, large-particle-size microcrystalline cellulose, lubricant, flow aid, and mannitol. This invention effectively solves the problems of utpatinib solubility being greatly affected by pH, unstable release, and easy tablet cracking under high hardness by constructing a synergistic system of pH adjustment and gel density, and by utilizing anhydrous citric acid to create an acidic microenvironment and enhance the strength of the HPMC gel layer, combined with the internal and external division of labor between small-particle-size and large-particle-size microcrystalline cellulose.

The invention belongs to the field of medicine cutting devices, and discloses a western medicine sustained release tablet cutting and positioning device which comprises a positioning pipe and a cutting pipe, the cutting pipe is slidably connected with a connecting shaft, the connecting shaft is connected with a connecting plate and a pressing part, the connecting plate and the inner wall of the cutting pipe are jointly connected with a second spring, the connecting plate is connected with a cutter, and the cutter is connected with a second spring. A clamping plate is rotatably connected to the inner wall of the positioning pipe, a sliding rod is connected to the inner wall of the positioning pipe, a sliding ring is slidably connected to the sliding rod, the clamping plate and the sliding ring are jointly and rotatably connected with a rotating rod, the sliding rod is sleeved with a first spring, and a medicine containing protruding block is connected to the inner wall of the positioning pipe. According to the scheme, through a flexible self-adaptive clamping and buffering segmentation structure, fragmentation is effectively prevented while tablets are segmented, immediate separation of fragments is achieved, and the accuracy and integrity of the dosage of the sustained release tablets are guaranteed.